(VIANEWS) – MAGNORA (MGN.OL), SELVAAG BOLIG (SBO.OL), X-FAB (XFAB.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MAGNORA (MGN.OL)
210.1% sales growth and 52.28% return on equity
Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, MAGNORA has a trailing twelve months EPS of kr3.95.
PE Ratio
MAGNORA has a trailing twelve months price to earnings ratio of 8.05. Meaning, the purchaser of the share is investing kr8.05 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.28%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Oct 26, 2023, the estimated forward annual dividend rate is 0.37 and the estimated forward annual dividend yield is 1.17%.
Volume
Today’s last reported volume for MAGNORA is 62798 which is 53.68% below its average volume of 135592.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MAGNORA’s EBITDA is -76.25.
More news about MAGNORA.
2. SELVAAG BOLIG (SBO.OL)
31.3% sales growth and 8.14% return on equity
Selvaag Bolig ASA, a housing development company, engages in the development, construction, and sale of residential properties in Greater Oslo, Bergen, Stavanger, Trondheim, and Stockholm. The company also offers project management services. Selvaag Bolig ASA was incorporated in 2008 and is headquartered in Oslo, Norway. Selvaag Bolig ASA is a subsidiary of Selvaag AS.
Earnings Per Share
As for profitability, SELVAAG BOLIG has a trailing twelve months EPS of kr1.94.
PE Ratio
SELVAAG BOLIG has a trailing twelve months price to earnings ratio of 17.65. Meaning, the purchaser of the share is investing kr17.65 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.14%.
More news about SELVAAG BOLIG.
3. X-FAB (XFAB.PA)
23.3% sales growth and 19.58% return on equity
X-FAB Silicon Foundries SE operates as an analog/mixed-signal semiconductor technology foundry. The company manufactures silicon wafers for automotive, industrial, consumer, medical, and mobile communications, and other applications; and analog/mixed-signal integrated circuits, sensors, and micro-electro-mechanical systems. It also provides manufacturing and design support services for customers that design analog/mixed-signal integrated circuits and other semiconductor devices, as well as engineering and prototyping, outsourcing, technical, and design support services. The company serves integrated device manufacturers, original equipment manufacturers, and fabless semiconductor companies. It operates in Belgium, Germany, the United Kingdom, Austria, France, Switzerland, Denmark, Sweden, Finland, Netherlands, Ireland, Singapore, China, Japan, Thailand, Malaysia, Korea, Taiwan, Hong Kong, New Zealand, the United States, and internationally. The company was founded in 1992 and is based in Tessenderlo, Belgium.
Earnings Per Share
As for profitability, X-FAB has a trailing twelve months EPS of €1.11.
PE Ratio
X-FAB has a trailing twelve months price to earnings ratio of 8.38. Meaning, the purchaser of the share is investing €8.38 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.58%.
Sales Growth
X-FAB’s sales growth is 31.6% for the present quarter and 23.3% for the next.
More news about X-FAB.
4. NAVAMEDIC (NAVA.OL)
20.7% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 31.78. Meaning, the purchaser of the share is investing kr31.78 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 51.9%, now sitting on 502.65M for the twelve trailing months.
More news about NAVAMEDIC.
5. DASSAULT SYSTEMES (DSY.PA)
7% sales growth and 13.44% return on equity
Dassault Systèmes SE provides software solutions and services worldwide. It offers SOLIDWORKS design software for mechanical and electronic printed circuit board design solutions, product data management, simulation, manufacturing, and technical communication; CATIA, an engineering and design software for product 3D computer-aided design; GEOVIA for intersection of natural resources, infrastructure and urban planning; and BIOVIA that develops chemicals, biologics, and materials experiences. The company provides SIMULIA that delivers realistic simulation applications; DELMIA, which enables global industrial operations; 3DVIA that provides 3D space planning solutions; and ENOVIA that enables to plan and track the definition of success for customer. In addition, it offers Centric PLM, a product lifecycle management software solution; 3DEXCITE, a real-time 3D visualization software; NETVIBES, which enables organizations to gather, align, and enrich big data; 3DEXPERIENCE platform that provides organizations a holistic and real-time view of their business activities and ecosystem, as well as connecting people, ideas, data, and solutions together in a single environment; and MEDIDATA, a clinical research study software that provides evidences and insights to pharmaceutical, biotech, medical device, and diagnostic companies, as well as academic researchers. It primarily serves companies in the transportation and mobility; industrial equipment; aerospace and defense; high-tech; life sciences and healthcare; energy and materials; home and lifestyle; construction, cities, and territories; consumer packaged goods and retail; marine and offshore; and business services. Dassault Systèmes SE was incorporated in 1981 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, DASSAULT SYSTEMES has a trailing twelve months EPS of €0.77.
PE Ratio
DASSAULT SYSTEMES has a trailing twelve months price to earnings ratio of 54.03. Meaning, the purchaser of the share is investing €54.03 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.44%.
Volume
Today’s last reported volume for DASSAULT SYSTEMES is 167010 which is 85.67% below its average volume of 1165740.
Yearly Top and Bottom Value
DASSAULT SYSTEMES’s stock is valued at €41.60 at 01:20 EST, under its 52-week high of €45.19 and way above its 52-week low of €33.10.
Earnings Before Interest, Taxes, Depreciation, and Amortization
DASSAULT SYSTEMES’s EBITDA is 103.45.
Moving Average
DASSAULT SYSTEMES’s worth is under its 50-day moving average of €42.65 and above its 200-day moving average of €38.91.
More news about DASSAULT SYSTEMES.
